Linatab M 2.5/1000 Tablet

What is Linatab M?

Linatab M is a fixed-dose combination tablet manufactured by Incepta Pharmaceuticals Ltd., combining the DPP-4 inhibitor Linagliptin with the biguanide Metformin. It offers dual-action blood glucose control for type 2 diabetes in a single tablet, reducing pill burden compared to taking each medicine separately.

Generic Name and Composition

Each tablet contains 2.5 mg of Linagliptin and 1000 mg of Metformin Hydrochloride.

Indications

• Type 2 diabetes mellitus in patients not adequately controlled on metformin alone
• Type 2 diabetes mellitus in patients already being treated with the combination of linagliptin and metformin as separate tablets, for treatment simplification
• Used as an adjunct to diet and exercise to improve glycemic control

How It Works — Mechanism of Action

Linagliptin inhibits the DPP-4 enzyme, increasing active incretin hormone levels that stimulate glucose-dependent insulin release and suppress glucagon secretion. Metformin reduces hepatic glucose production, decreases intestinal glucose absorption, and improves peripheral insulin sensitivity. Together, these complementary mechanisms provide more comprehensive blood glucose control than either agent alone.

Dosage and Administration

• Dosage is individualized by a physician based on the patient's current metformin dose and glycemic response.
• Typically taken twice daily with meals to minimize gastrointestinal side effects.
• Swallow the tablet whole with water — do not crush or chew unless instructed otherwise.
• If a dose is missed, take it with the next meal; do not double up.

Side Effects

Common: Nausea, diarrhea, abdominal discomfort, metallic taste, nasopharyngitis.

Uncommon: Hypoglycemia (mainly when combined with sulfonylureas or insulin), reduced appetite, vitamin B12 deficiency with long-term use.

Rare: Lactic acidosis, pancreatitis, severe allergic reactions (angioedema, urticaria, anaphylaxis), bullous pemphigoid.

Drug Interactions

Increased lactic acidosis risk: Iodinated contrast media, excessive alcohol intake.

Increased hypoglycemia risk: Sulfonylureas, insulin.

May affect blood glucose control: Corticosteroids, diuretics, strong CYP3A4/P-glycoprotein inducers (e.g., rifampicin).

Contraindications

• Severe renal impairment
• Known hypersensitivity to linagliptin, metformin, or any excipient
• Acute or chronic metabolic acidosis, including diabetic ketoacidosis
• Conditions predisposing to tissue hypoxia (severe heart failure, respiratory failure, recent myocardial infarction)

Pregnancy and Lactation

Safety of this combination in pregnancy and breastfeeding has not been firmly established; insulin is generally preferred for glycemic control during pregnancy. Consult a physician before use if pregnant, planning pregnancy, or breastfeeding.

Precautions and Warnings

• Temporarily discontinue before procedures involving iodinated contrast media, as advised by your physician.
• Use with caution in patients with reduced kidney function; periodic renal function monitoring is recommended.
• Watch for symptoms of pancreatitis (persistent severe abdominal pain) and discontinue promptly if suspected.
• Seek immediate medical attention for symptoms of lactic acidosis (unusual muscle pain, difficulty breathing, abdominal pain, severe tiredness).
• Avoid excessive alcohol intake.

Overdose

Overdose may lead to lactic acidosis (from the metformin component), presenting with malaise, abdominal pain, and difficulty breathing — a medical emergency requiring immediate hospital care, potentially including hemodialysis. Significant hypoglycemia from linagliptin alone is unlikely.

Storage Instructions

• Store below 30°C in a cool, dry place, away from direct sunlight and moisture.
• Keep out of reach of children.
• Do not use after the expiry date printed on the pack.

Frequently Asked Questions

Q1: Why is Linatab M taken twice daily?
The metformin component is typically dosed twice daily with meals to maintain steady blood levels and minimize gastrointestinal side effects.

Q2: Can I switch directly from separate linagliptin and metformin tablets to Linatab M?
Yes, your physician can switch you to the combination tablet matching your current doses of each component for convenience.

Q3: Will Linatab M cause low blood sugar?
The risk of hypoglycemia is low when used alone, since neither linagliptin nor metformin independently stimulates excess insulin release; risk increases when combined with sulfonylureas or insulin.

Q4: How does Linatab M 2.5/1000 differ from Linatab M 2.5/850 or 2.5/500?
All contain the same 2.5mg linagliptin dose; the metformin component differs (1000mg, 850mg, or 500mg), allowing the physician to titrate the metformin dose to the patient's tolerability and glycemic needs.

Medical Disclaimer

This product is available by prescription only (Rx) and should be used under medical supervision. The information provided is for educational purposes and does not replace professional medical advice. Always consult a registered physician before starting, stopping, or changing any medication. DiabetesStore.com.bd is a licensed online pharmacy in Bangladesh.